SKP2 High Expression, KIT Exon 11 Deletions, and Gastrointestinal Bleeding as Predictors of Poor Prognosis in Primary Gastrointestinal Stromal Tumors

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Lv, Ang ^a   Li, Zhongwu ^a   Tian, Xiuyun ^a   Guan, Xiaoya ^a   Zhao, Min ^a   Dong, Bin ^a   Hao, Chunyi ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CD133 ANTIGEN; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P27; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR MARKER; S PHASE KINASE ASSOCIATED PROTEIN; STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; EPITHELIOID CELL; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE C KIT; PDGFRALPHA ONCOGENE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TISSUE MICROARRAY; TREND STUDY; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR NECROSIS; TUMOR VOLUME; BLEEDING; GASTROINTESTINAL STROMAL TUMORS; GENETICS; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; RISK ASSESSMENT;

FEMALE; GASTROINTESTINAL STROMAL TUMORS; HEMORRHAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MITOTIC INDEX; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; S-PHASE KINASE-ASSOCIATED PROTEINS; SEQUENCE DELETION; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877850694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062951     Document Type: Article

References (41)

1. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-basedstudy in western Sweden. Cancer 103: 821-829.
2. Mucciarini C, Rossi G, Bertolini F, Valli R, Cirilli C, et al. (2007) Incidence and clinicopathologic features of gastrointestinal stromal tumors: a population-based study. BMC Cancer 20 (7): 230.
3. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58.
4. DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, et al. (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-1104.
5. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, et al. (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459-465.
6. Miettinen M, Lasota J, (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83.
7. Joensuu H, (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411-1419.
8. Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, et al. (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13 (3): 265-274.
9. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T, (2003) Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 6: 39-48.
10. Di Vizio D, Demichelis F, Simonetti S, Pettinato G, Terracciano L, et al. (2008) Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer 13 (8): 134.
11. Tazawa T, Tsukada K, Makuuchi H, Tsutsumi Y, (1999) An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol Int 49: 786-798.
12. Arne G, Kristiansson E, Nerman O, Kindblom LG, Ahlman H, et al. (2011) Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer 129 (5): 1149-1161.
13. Ruiz-Tovar J, Diez-Tabernilla M, Housari G, Martinez-Molina E, Sanjuanbenito A, (2010) Gastrointestinal stromal tumors: actin expression, a new prognostic factor? Am Surg 76 (11): 1244-1250.
14. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
15. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710.
16. Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, et al. (2006) Gastrointestinal Stromal Tumors With KIT Exon 11 Deletions Are Associated With Poor Prognosis. Gastroenterology 130 (6): 1573-1581.
17. Lasota J, Dansonka-Mieszkowska A, Stachura T, Schneider-Stock R, Kallajoki M, et al. (2003) Gastrointestinal stromal tumors with internal tandem duplications in 3′end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 16: 1257-1264.
18. Antonescu C, Sommer G, Sarran L, Tschernyavsky S, Riedel E, et al. (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9: 3329-3337.
19. Lasota J, Dansonka-Mieszkowska A, Sobin L, Miettinen M, (2004) A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84: 874-883.
20. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, et al. (2005) Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 11: 638-645.
21. Shirin H, Kravtsov V, Shahmurov M, Shabat VS, Krinshpon I, et al. (2007) The Cyclin-Dependent Kinase Inhibitor, p27kip1, Has No Correlation with the Malignant Potential of GIST. Digestion 75 (1): 4-9.
22. Cerski MR, Pereira F, Matte US, Oliveira FH, Crusius FL, et al. (2011) Exon 11 mutations, Ki67, and p16INK4A as predictors of prognosis in patients with GIST. Pathol Res Pract 207 (11): 701-706.
23. Artigiani Neto R, Logullo AF, Stávale JN, Lourenço LG, (2012) Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST). Acta Cir Bras 27 (5): 315-321.
24. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV, (2003) Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 21 (4): 722-727.
25. Cates JM, Friedman DB, Seeley EH, Dupont WD, Schwartz HS, et al. (2010) Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis. Int J Exp Pathol 91 (4): 335-349.
26. Miettinen M, Sobin L, Lasota J, (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long term follow up. Am J Surg Pathol 29: 52-68.
27. Wong NA, Young R, Malcomson RD, Nayar AG, Jamieson LA, et al. (2003) Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 43: 118-126.
28. Meara RS, Cangiarella J, Simsir A, Horton D, Eltoum I, et al. (2007) Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53. Cytopathology 18 (5): 283-289.
29. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, et al. (2002) Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down regulation. Mod Pathol 15 (11): 1227-1235.
30. Carrano AC, Eytan E, Hershko A, Pagano M, (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1 (4): 193-199.
31. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, et al. (2001) Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A 98 (5): 2515-2520.
32. Hershko DD, Shapira M, (2006) Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 107 (4): 668-675.
33. Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, et al. (2012) Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas. PLoS One 7 (10): e47068.
34. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, et al. (2009) Cell Cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 15: 4191-4198.
35. Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Løberg EM, et al. (2008) Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol 21: 46-53.
36. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, et al. (2005) Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal tumor and the relevance of the risk grade. Human Pathol 36: 828-837.
37. Gelen TG, Elpek GO, Aksoy NH, Ogüş M, Keleş N, (2003) p27 labeling index and proliferating gastrointestinal stromal tumors: correlations with clinicopathologic factors and recurrence. Jap J Clin Oncol 33: 346-352.
38. L Zong, P Chen, Y Xu, (2012) Correlation between P53 expression and malignant risk of gastrointestinal stromal tumors: Evidence from 9 studies. Eur J Surg Oncol 38 (3): 189-195.
39. Martin J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, et al. (2005) Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23: 6190-6198.
40. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, et al. (2005) 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 104: 159-169.
41. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M, (2007) Mutations in gastrointestinal stromal tumors-a population-based study from Northern Norway. APMIS 115: 289-298.